Researchers have created an artificial intelligence (AI)-enabled implantable bio-sensing device that can change shape and adapt to maintain drug treatment and bypass scar tissue build up. As the foreign body response continues to impact the longevity of implantable medical devices that treat many conditions, the researchers hope that the Fibrosensing Dynamic Soft Reservoir (FSDSR), capable of monitoring fibrotic capsule formation and overcoming its effects via soft robotic actuations, can change the way patients body respond to therapeutic treatments.
A Spanish study led by scientists from the Cajal Institute and the National Center of Oncological Research (CNIO) combined the power of artificial neural networks and biological neuronal circuits to identify abnormal brain activity produced by secondary metastases in the CNS and classify these tumors. The work, published online on Aug. 30, 2023, in Cancer Cell, showed how damage in the brain did not depend on the tumor size but on the effect it produced on neuronal circuits, interrupting cell communication.
The U.K. government’s recent allocation of £13 million (US$16.5 million) to fund research that will deliver cutting-edge artificial intelligence (AI) projects is a sign of its ongoing commitment to use the latest innovative technologies to modernize the health care sector. However, a group of MPs have released a report which warned that although AI offers significant opportunities there remains governance challenges that must be addressed.
Data-driven health care platform company Kakao Healthcare Corp. may be embarking on its most ambitious project yet: launching an effective “AI-platform bridge” over patient waters to connect medical institutions, government and the industry for novel drug discovery and research.
Two papers published in Nature on Aug. 23, 2023, describe brain computer interfaces (BCI) with unprecedented capabilities for decoding brain activity into sentences, translating at speeds around half that of normal speech, and with vocabularies exceeding 1,000 words.
The French National Insurance Fund, known as La Caisse Nationale d’Assurance Maladie, a division reporting to the Ministry of Health and the Ministry of Economics and Finance in France, has released its annual report containing proposals aimed at achieving financial balance in the nation’s health insurance expenditures. The 100-page document will be submitted to the parliament to be voted upon this fall. “These are precise, concrete recommendations drawn up after an in-depth analysis of trends in expenditure and practices,” said Thomas Fatôme, general director of the National Insurance Fund.
Cathvision ApS received U.S. FDA clearance for two artificial intelligence (AI) models, the PVI Analyzer, and Signal Complexity, which are part of a suite of algorithms designed to help electrophysiologists improve the diagnosis and treatment of complex atrial arrhythmias, including atrial fibrillation. The two algorithms are part of Cathvision’s Cardialytics suite of AI-powered analytics integrated into its Ecgenius system, an electrophysiology recording system that helps with electrogram interpretation.
Hypertrophic cardiomyopathy (HCM) might not be the talk of the town in the world of cardiology medical devices, but the condition has a devastating effect on a large number of lives, particularly in the case of early disease onset. San Francisco-based Viz.ai Inc. has won a de novo from the U.S. FDA for its algorithm for identification of patients at risk of HCM, the aptly named Viz HCM, a product the company believes will not only save lives but may save the U.S. health care system a large amount of money as well.
The U.S. FDA’s position on predetermined change control protocols (PCCPs) is still in draft form, even though at least one company has won a marketing authorization with a PCCP attached to the underlying artificial intelligence (AI) algorithm. While the agency is still on the fence about a PCCP that incorporates a potential change in the indication for use, regulatory attorney Brigid DeCoursey Bondoc told BioWorld that industry should not reflexively avoid proposing a PCCP with a such change so long as the proposal includes answers to the questions the FDA is sure to ask.
Artificial intelligence (AI) has been approved for use in the U.K. National Health Service (NHS) for the first time, after passing an expedited health technology assessment.
